Modulating the cholinergic system—Novel targets for deep brain stimulation in Parkinson's disease
Journal of Neurochemistry · 2025
DOI: 10.1111/jnc.16264 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Neurochemistry, 2025. Verfasst von V Witzig und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, RWTH Aachen University, Aachen, Germany. Hauptthemen laut MEDLINE: Deep Brain Stimulation, Parkinson Disease, Cholinergic Neurons. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 231 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Fakultät, RWTH Aachen University.
Abstract (Originalsprache)
Parkinson's disease (PD) is the second‐fastest growing neurodegenerative disease in the world. The major clinical symptoms rigor, tremor, and bradykinesia derive from the degeneration of the nigrostriatal pathway. However, PD is a multi‐system disease, and neurodegeneration extends beyond the degradation of the dopaminergic pathway. Symptoms such as postural instability, freezing of gait, falls, and cognitive decline are predominantly caused by alterations of transmitter systems outside the classical dopaminergic axis. While levodopa and deep brain stimulation (DBS) of the subthalamic nucleus or globus pallidus internus effectively address PD primary motor symptoms, they often fall short in mitigating axial symptoms and cognitive impairment. Along these lines, the cholinergic system is increasingly recognized to play a crucial role in governing locomotion, postural stability, and cognitive function. Thus, there is a growing interest in bolstering the cholinergic tone by DBS of cholinergic targets such as the pedunculopontine nucleus (PPN) and nucleus basalis of Meynert (NBM), aiming to alleviate these debilitating symptoms resistant to traditional treatment strategies targeting the dopaminergic network. This review offers a comprehensive overview of the role of cholinergic dysfunction in PD. We discuss the impact of PPN and NBM DBS on the management of symptoms not readily accessible to established DBS targets and pharmacotherapy in PD and seek to provide guidance on patient selection, surgical approach, and stimulation paradigms. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, RWTH Aachen University, Aachen, Germany.
- Department of Neurosurgery, RWTH Aachen University, Aachen, Germany.
- Department of Stereotactic and Functional Neurosurgery, University Hospital Cologne, Cologne, Germany.
- Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium.
- Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
- JARA-BRAIN Institute Molecular Neuroscience and Neuroimaging, Jülich Research Center GmbH and RWTH Aachen University, Aachen, Germany.
ORCID-Profile: V Witzig, J B Schulz
Förderung
- Medizinische Fakultät, RWTH Aachen University
Zitieren
APA
Witzig, V., Pjontek, R., Tan, S. K. H., Schulz, J. B., & Holtbernd, F. (2025). Modulating the cholinergic system—Novel targets for deep brain stimulation in Parkinson's disease. Journal of Neurochemistry. https://doi.org/10.1111/jnc.16264
Vancouver
Witzig V, Pjontek R, Tan SKH, Schulz JB, Holtbernd F. Modulating the cholinergic system—Novel targets for deep brain stimulation in Parkinson's disease. Journal of Neurochemistry. 2025. doi:10.1111/jnc.16264
BibTeX
@article{Witzig2025,
author = {Witzig, V and Pjontek, R and Tan, S K H and Schulz, J B and Holtbernd, F},
title = {Modulating the cholinergic system—Novel targets for deep brain stimulation in Parkinson's disease},
journal = {Journal of Neurochemistry},
year = {2025},
doi = {10.1111/jnc.16264}
}
EUVIMED